Josune Ayo, CEO and cofounder of Genbioma: “ with the support of Innovation and CDTI MRR funds, we have consolidated our leadership in the development of functional ingredients postbióticos glucose to control through regulation biota growth "

The metabolic diseases, including type 2 diabetes and obesity are now a major public health challenges at global level. Its increasing prevalence affects millions of people and is associated with increased cardiovascular risk, a significant loss of quality of life and health costs. The persistence of hyperglycemia, insulin resistance and imbalances glucídicos largely explain the high prevalence of these pathologies, increasingly common even among young people. Therefore, it is key to promote strategies to act on the regulatory mechanisms of metabolism. In this regard, the balance of intestinal biota growth represents a natural way and complementary to the prevention, with great potential to modulate safely and effectively metabolic disturbances from an early stage.

From this idea was born Genbioma, a biotechnology company founded in june 2019, Navarra, by a team of experts with extensive experience in industrial development of probiotics. The company, which also has the participation of the public university of Navarra (UPNA) and the university of Navarra (UNAV) as part of its scientific advisory council, is focused on redefining the metabolic health through the study of intestinal microbioma.

As explained Josune Ayo, CEO and cofounder of Genbioma: “ We believe in the power of microbioma to prevent the development of metabolic diseases and cardiovascular diseases and to improve health through biota growth ”.

For this reason, it is clear: to improve the health of people through probiotic product and postbióticos, recent secondary that maintain a high stability and a remarkable bioactividad through balance intestinal biota growth.

Genbioma has developed an advanced technology platform, to identify and create new biotic from bacterial strains with potential to regulate glucose metabolism. These are marketed as ingredients and nutritional supplements, safe and natural backed by scientific evidence. Thanks to the use of tools and metabolómicas metagenómicas, together with a model of rapid detection based on Caenorhabditis elegans — a small nematode widely used in research to study the relationship between bacteria, metabolism and health — the company you can select expeditiously the most promising strains to improve the health metabolic in people with type 2 diabetes, prediabetes and obesity.

With a clear orientation towards the international market, the company seeks to revolutionize the strategy of preventive health to develop a new generation of biotic acting through the intestinal biota growth to prevent and reduce complications. Their vision is to become the leading company in postbióticos probiotic ingredients and scientifically proven metabolic health, always under an ethical approach, sustainable and aligned with the objectives of Sustainable Development.

As summarized Ayo: “ our aim is to democratize access to effective microbioma products, natural, insurance and endorsed by science, but that they can also be included in food within the diet to contribute to a more healthy and responsible for all ”.

The team, led by Genbioma Josune Ayo, combines science, innovation and social commitment to transform the metabolic health

Cutting-edge research: progress in the study of microbioma

The support of CDTI innovation through Neotec programme, funded by the european funds recovery Mechanism and resilience (MRR), has enabled Genbioma beareth laboratory research on the market. This support, the company has been scientifically validated their solutions, increase production and distribute their products internationally. Your developments focus on improving the regulation of glucose in blood and probiotic postbióticos of new generation, i.e. beneficial bacteria or inactivated that help to balance the intestinal biota growth.

As explained the co-founder: “ The health and well-being are closely linked to the ecosystem of microorganisms in the intestine: biota growth. There is increasing evidence that certain bacteria can regulate the metabolism and contribute to improving health in general ”.

The project started by identifying bacteria with greater capacity to control blood sugar, using advanced techniques to assess their impact on metabolism and intestinal balance. This selection, developed the ingredient Genbioma probiótico pA1c ®, and its derivative postbiótico pA1c ® HI, as well as combinations with other natural ingredients that potentiate their effects. The initial survey showed that these formulations helping sustain stable glucose, reduce the inflammation and improve the way in which the managing body fat.

According to the CEO: “ Favours the diversity of intestinal bacteria, reducing the harmful and potentially beneficial. This translates into a better response to the insulin and more effective control blood sugar through the activation of metabolism own ”.

Currently, the HI postbiótico pA1c ® has been tested in people with prediabetes and obesity, showing improvements in levels of sugar and approaching patients to normal values. The hotel is located in the clinical testing stage with people diagnosed with type 2 diabetes, in collaboration with four hospitals in spain.

In the words of Ayo: “ The support of the CDTI has allowed in the development of functional ingredients and transforming scientific research in solutions that have a real impact on metabolic health ”.

Enhance health and support existing treatments

Genbioma products not only seek to help control blood sugar, but could also be supplemented with medical treatments. The act on the intestinal biota growth, these probiotics and postbióticos can improve metabolism and promoting itself more stable control of glucose in the long term.

As explained Ayo: “ our probiótico could be combined with treatments as metformin or semaglutida, offering an alternative natural that helps to keep under control, sugar improves the agency's response and slows down the progression of diabetes ”.

The preclinical studies and the first clinical trials show that eca probiótica pA1c ® and its derivative postbiótico pA1c ® HI, act synergistically with certain drugs, enhance its impact and delay the evolution of the disease. In Addition, the stability of the postbiótico facilitates their incorporation into functional food and beverages, expanding nutritional intervention options.

“ our goal is to offer solutions that not only benefit those who are already alterations in sugar, but also help to prevent complications and delay the need for medication ”, add the CEO.

Present stage of the company

After years of research, today Genbioma has reached a consolidation phase, scientific and commercial products clinically and validated a business model aimed at the international expansion. According To the CEO explains: “ To date, we have made significant progress in scientific validation, industrial scaling and international agreements ”.

In parallel, the HI postbiótico Reglubetic ® has shown improvement in blood glucose and lipid metabolism in people with prediabetes and obesity, while clinical trials on patients with type 2 diabetes continues to move forward. In addition, the company has established agreements with manufacturers of probiotics and protected their knowledge by international patents, assuring the exclusivity of strains and formulations.

“ our model allows us to combine scientific innovation with the commercial viability, leading products with real impact those at risk of metabolic diseases ”, detailing the co-founder.

On the other hand, Genbioma explores markets in Spain, europe, latin america and Asia, with distribution agreements already established in six countries in the balkans. Thanks to this consolidation, Genbioma not only succeeded in exporting products research to apply, but has also laid the foundations for new lines of development.

Reglubetic ® HI, postbiótico developed by Genbioma to improve glucose metabolism and balance the intestinal biota growth in people with impaired glucose intolerance

Leading the new generation of solutions

For Josune Ayo, direct Genbioma has been a challenge both the scientific and human. “ I am proud to lead a team working towards positioning the company at the international level as a pioneer in the development of a new generation of products based on biota growth — probiotics, postbióticos and symbiotic — aimed at preventing metabolic diseases with high prevalence, ” explains.

“ women entrepreneurs, As one of the challenges are further moves in a project which is already starting to be commercially viable and with a social impact that attracts investors around the world ”, add the CEO.

These challenges have enabled Genbioma achieve significant milestones in innovation, validation, clinical and international expansion.

Looking ahead: impact and prevention

Genbioma look forward to continue to innovate in metabolic health and reach more people around the world. The company plans to develop new solutions postbióticas that, in addition to regulate glucose, can help monitor cholesterol and blood pressure, thereby broadening its impact on the prevention of cardiovascular diseases and metabolic diseases.

“ our goal is that each product to act preventively and practice, by helping people to maintain a healthy metabolism before they arise most serious problems, ” explains Ayo.

Therefore, the company look to their products not only support to those who already have metabolic disorders, but also to be a tool of prevention, accessible for the whole population. "With innovation, science and social commitment, Genbioma demonstrates how biotechnology could transform the prevention and care of metabolic health globally" concludes.

CDTI Innovation

The centre for technological development and innovation, CDTI E.P.E. is the agency for innovation of the ministry of science, innovation and universities, whose goal is the promotion of technological innovation in business. The CDTI mission is to ensure that the business fabric english generates and transform knowledge into growth científico-técnico globally competitive, sustainable and inclusive. By 2024, within the framework of a new strategic plan, the CDTI provided more than $2.3 billion euros of support for business startups and spain.

More information:

Office of the press
prensa@cdti.es
91-581.55.00

On The Internet
Website:www.cdti.es
In Linkedin:https :// www.linkedin.com/company/29815
X:https :// twitter.com/CDTI _ innovation
On Youtube:https :// www.youtube.com/user/CDTIoficial
This content is copyright © 2025 CDTI, Soes. Permitted for use and reproduction by quoting the source and digital identity of CDTI (@CDTI _ innovation).